Skip to main content
SpringerLink
Log in

Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches

  • Chapter
  • First Online:
Gastrointestinal Pharmacology

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 239))

Abstract

Inflammatory bowel diseases, most commonly categorized as Crohn’s disease and ulcerative colitis, are immune mediated chronic inflammatory disorders of the gastrointestinal tract. The etiopathogenesis is multifactorial with different environmental, genetic, immune mediated, and gut microbial factors playing important role. The current goals of therapy are to improve clinical symptoms, control inflammation, prevent complications, and improve quality of life. Different therapeutic agents, with their indications, mechanisms of action, and side effects are discussed in this chapter. Anti-integrin therapy, a newer therapeutic class, with its potential beneficial role in both Crohn’s disease and ulcerative colitis is also mentioned. In the end, therapeutic algorithms for both diseases are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abegunde AT, Muhammad BH, Bhatti O, Ali T (2016) Environmental risk factors for inflammatory bowel diseases: evidence based literature review. World J Gastroenterol 22(27):6296–317

    Article  PubMed  PubMed Central  Google Scholar 

  • Abreu MT, Fukata M, Arditi M (2005) TLR signaling in the gut in health and disease. J Immunol 174:4453–4460

    Article  CAS  PubMed  Google Scholar 

  • Akerkar GA, Peppercorn MA, Hamel MB (1997) Corticosteroid-associated complications in elderly Crohn’s disease patients. Am J Gastroenterol 92:461–464

    CAS  PubMed  Google Scholar 

  • Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, Richter JM, Fuchs CS, Chan AT (2012) Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology 142:482–489

    Article  CAS  PubMed  Google Scholar 

  • Andrews WW et al (2003) Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Obstet Gynecol 101:847–855

    Article  CAS  PubMed  Google Scholar 

  • Armuzzi A, Gionchetti P, Daperno M, Danese S et al (2016) Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe inflammatory bowel disease. Dig Liver Dis 48:360–337

    Article  CAS  PubMed  Google Scholar 

  • Bayer A, Gajewska A, Stephens M, Stark JM, Pathy J (1987) Pharmacokinetics of ciprofloxacin in the elderly. Respiration 51:292–295

    Article  CAS  PubMed  Google Scholar 

  • Ben-Horin S et al (2010) Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 8:475–476

    Article  PubMed  Google Scholar 

  • Ben-Horin S et al (2011) Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 5:555–558

    Article  PubMed  Google Scholar 

  • Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G (1995) Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 172:525–529

    Article  CAS  PubMed  Google Scholar 

  • Cantorna MT, Zhu Y, Froicu M, Wittke A (2004) Vitamin D status,1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 80:1717S–1720S

    CAS  PubMed  Google Scholar 

  • Carla-Moreau A, Paul S, Roblin X, Genin C, Peyrin-Biroulet L (2015) Prevention and treatment of postoperative Crohn’s disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. Dig Liver Dis 47(3):191–196

    Article  CAS  PubMed  Google Scholar 

  • Caro-Paton T et al (1997) Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44:179–182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Castiglione F, Rispo A, Di Girolamo E, Cozzolino A, Manguso F, Grassia R, Mazzacca G (2003) Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn’s disease. Aliment Pharmacol Ther 18(11–12):1107

    Article  CAS  PubMed  Google Scholar 

  • Cho JH, Brant SR (2011) Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140:1704–1712

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cobrin GM, Abreu MT (2005) Defects in mucosal immunity leading to Crohn’s disease. Immunol Rev 206:277–295

    Article  CAS  PubMed  Google Scholar 

  • Coelho J, Beaugerie L, Colombel JF et al (2011) Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 60:198–203

    Article  PubMed  Google Scholar 

  • Cohen RD, Woseth DM, Thisted RA, Hanauer SB (2000) A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95:1263–1276

    Article  CAS  PubMed  Google Scholar 

  • Colombel JF, Sandborn WJ, Rutgeerts P et al (2007a) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65

    Article  CAS  PubMed  Google Scholar 

  • Colombel JF, Sandborn WJ, Rutgeerts P et al (2007b) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65

    Article  CAS  PubMed  Google Scholar 

  • Colombel JF, Sandborn WJ, Reinisch W et al (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362:1383–1395

    Article  CAS  PubMed  Google Scholar 

  • Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ (2015) Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease – a SONIC post hoc analysis. Aliment Pharmacol Ther 41:734–746

    Article  CAS  PubMed  Google Scholar 

  • Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P et al (2010) NOD2 stimu-lation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16:90–97

    Article  CAS  PubMed  Google Scholar 

  • Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A (2011) Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 9:30–35

    Article  CAS  PubMed  Google Scholar 

  • Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM (2015) Ulcerative colitis care pathway. Gastroenterology 149:238–245

    Article  PubMed  Google Scholar 

  • Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, Ananthakrishnan AN (2013a) Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 19:309–315

    Article  PubMed  PubMed Central  Google Scholar 

  • Desai A, Zator ZA, deSilva P et al (2013b) Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 19:309–315

    Article  PubMed  PubMed Central  Google Scholar 

  • Dubinsky M, Mahadevan U, Vermeire S, Abhyankar B, Lasch K (2015) Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. P563. ECCO

    Google Scholar 

  • El MM, El-Hachem S, Harrison JR, Binion DG (2010) Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets 11:234–241

    Article  Google Scholar 

  • Feagan BG, Rochon J, Fedorak RN et al (1995) Methotrexate for the treatment of Crohn’s disease. the North American Crohn’s Study Group Investigators. N Engl J Med 332:292–297

    Article  CAS  PubMed  Google Scholar 

  • Feagan BG, Fedorak RN, Irvine EJ et al (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 342:1627–1632

    Article  CAS  PubMed  Google Scholar 

  • Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699–710

    Article  CAS  PubMed  Google Scholar 

  • Feagan BG, McDonald JW, Panaccione R et al (2014a) Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 146:681–688

    Article  CAS  PubMed  Google Scholar 

  • Feagan BG, McDonald JWD, Panaccione R et al (2014b) Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 146:681–688

    Article  CAS  PubMed  Google Scholar 

  • Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P (2007) Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 13:123–128

    Article  PubMed  Google Scholar 

  • Ford AC, Bernstein CN, Khan KJ et al (2011) Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106:590–599

    Article  CAS  PubMed  Google Scholar 

  • Frei P, Biedermann L, Nielsen OH, Rogler G (2013) Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 19(7):1040–1048

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, Johansson R, Ferrieri A, Poggioli G, Campieri M (1999) Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 13(6):713

    Article  CAS  PubMed  Google Scholar 

  • Greenberg GR, Feagan BG, Martin F et al (1994) Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 331:836–841

    Article  CAS  PubMed  Google Scholar 

  • Greenwald DA, Brandt LJ (2003) Inflammatory bowel disease after age 60. Curr Treat Options Gastroenterol 6:213–225

    Article  PubMed  Google Scholar 

  • Gudsoorkar VS, Abraham BP (2015) Inflammatory bowel disease in the elderly: hazards of generalizing the evidence. Pract Gastroenterol 39(8):26–40

    Google Scholar 

  • Haber CJ, Meltzer SJ, Present DH, Korelitz BI (1986) Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 91:982–986

    Article  CAS  PubMed  Google Scholar 

  • Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549

    Article  CAS  PubMed  Google Scholar 

  • Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Humananti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333

    Article  CAS  PubMed  Google Scholar 

  • Hebuterne X, Lemann M, Bouhnik Y et al (2012) Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 62:201–208

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hosseini-Carroll P, Mutyala M, Seth A et al (2015) Pregnancy and inflammatory bowel diseases. World J Gastrointest Pharmacol Ther 6(4):156–171

    Article  PubMed  PubMed Central  Google Scholar 

  • Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn WJ (2007) Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Crohn’s and Colitis Foundation of America Clinical Alliance. Inflamm Bowel Dis 13(10):1250

    Article  PubMed  Google Scholar 

  • Ishida K, Inoue T, Fujiwara K et al (2013) Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients. World J Gastroenterol 19:2676–2682

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jarnerot G, Rolny P, Sandberg-Gertzen H (1985) Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89:1005–1013

    Article  CAS  PubMed  Google Scholar 

  • Kandiel A, Fraser AG, Korelitz BI et al (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54:1121–1125

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Abadir A, Marshall JK, Talley NJ, Moayyedi P (2011) Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 106(4):661

    Article  CAS  PubMed  Google Scholar 

  • Klebanoff MA et al (2001) Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 345:487–493

    Article  CAS  PubMed  Google Scholar 

  • Kornbluth A, Sachar DB (2010) Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 105:501–523

    Article  PubMed  Google Scholar 

  • Laharie D, Bourreille A, Branche J et al (2012) Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380:1909–1915

    Article  CAS  PubMed  Google Scholar 

  • Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH (1992) Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 23:328–364

    Article  CAS  PubMed  Google Scholar 

  • LeBel M, Barbeau G, Bergeron MG, Roy D, Vallee F (1986) Pharmacokinetics of ciprofloxacin in elderly subjects. Pharmacotherapy 6:87–91

    Article  CAS  PubMed  Google Scholar 

  • Leman M, Mary J-Y, Duclos B et al (2006) Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 130:1054–1061

    Article  CAS  Google Scholar 

  • Lichtenstein GR, Abreu MT, Cohen R et al (2006) American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130:940–987

    Article  CAS  PubMed  Google Scholar 

  • Lichtenstein GR, Hanauer SB, Sandborn WJ (2012) Risk of biologic therapy-associated progressive multifocal leukoencephalopathy: use of the JC virus antibody assay in the treatment of moderate-to-severe Crohn’s disease. Gastroenterol Hepatol 8(11 Suppl 8):1–20

    Google Scholar 

  • Liu JZ, Van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A et al (2015) Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 47(9):979–986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S (2015) Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. doi:10.1111/apt.13294. Epub ahead of print

    PubMed  Google Scholar 

  • Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD (2010) Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 8:268–274

    Article  PubMed  PubMed Central  Google Scholar 

  • Mahadevan U et al (2012) PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Updated presentation at the DDW 2012. Gastroenterology 142(Suppl 5):S149

    Article  Google Scholar 

  • Mahadevan U et al (2013) Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11:286–292

    Article  CAS  PubMed  Google Scholar 

  • McKenzie SA, Selley JA, Agnew JE (1975) Secretion of prednisolone into breast milk. Arch Dis Child 50:894–896

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nazareth M, Cristiano L, Kooijmans M (2008) Natalizumab use during pregnancy. Am J Gastroenterol 104:S114

    Google Scholar 

  • Panaccione R, Ghosh S, Middleton S et al (2014) Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146:392–400

    Article  CAS  PubMed  Google Scholar 

  • Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62(6):385–392

    Article  CAS  PubMed  Google Scholar 

  • Peyrin-Biroulet L, Sandborn W, Sands BE et al (2015) Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110(9):1324–1338. doi:10.1038/ajg.2015.233

    Article  CAS  PubMed  Google Scholar 

  • Present DH, Meltzer SJ, Krumholz MP et al (1989) 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111:641–649

    Article  CAS  PubMed  Google Scholar 

  • Probert CSJ, Dignass AU, Lindgren S, Pool MO, Marteau P (2014) Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis 8(3):200–207

    Article  PubMed  Google Scholar 

  • Reenaers C, Louis E, Belaiche J et al (2012) Does co-treatment with immunosuppressors improve outcome in patients with Crohn’s disease treated with adalimumab? Aliment Pharmacol Ther 36:1040–1048

    Article  CAS  PubMed  Google Scholar 

  • Reinisch W, Sandborn WJ, Hommes DW et al (2011) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60:780–787

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg JL, Levin B, Wall AJ, Kirsner JB (1975) A controlled trial of azathioprine in Crohn’s disease. Am J Dig Dis 20(8):721–726

    Article  CAS  PubMed  Google Scholar 

  • Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F et al (1995) Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108:1617–1621

    Article  CAS  PubMed  Google Scholar 

  • Rutgeerts P, Feagan BG, Lichtenstein GR et al (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:402–413

    Article  CAS  PubMed  Google Scholar 

  • Rutgeerts P, Sandborn WJ, Feagan BG et al (2005a) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476

    Article  CAS  PubMed  Google Scholar 

  • Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F et al (2005b) Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856–861

    Article  CAS  PubMed  Google Scholar 

  • Rutgeerts P, Van Assche G, Sandborn WJ et al (2012) Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 142:1102–1111

    Article  CAS  PubMed  Google Scholar 

  • Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, Nichols T, Targan S, Fleishman C, Wiita B (1997) A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92(10):1867–1871

    CAS  PubMed  Google Scholar 

  • Sandborn WJ, Colombel JF, Enns R, Feagan BG et al (2005) Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 353(18):1912–1925

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, Rutgeerts P, Enns R et al (2007a) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829–838

    Article  PubMed  Google Scholar 

  • Sandborn WJ, Feagan BG, Stoinov S et al (2007b) Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 357:228–238

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, Abreu MT, D’Haens G et al (2010) Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 8:688–695

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, van Assche G, Reinisch W et al (2012) Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142:257–265

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction andmaintenance therapy for Crohn’s disease. N Engl J Med 369:711–721

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, Feagan BG, Marano C et al (2014a) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85–95

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, Feagan BG, Marano C et al (2014b) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1):96–109

    Article  CAS  PubMed  Google Scholar 

  • Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885

    Article  CAS  PubMed  Google Scholar 

  • Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F (2010) Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 105:162–169

    Article  CAS  PubMed  Google Scholar 

  • Schreiber S, Khaliq-Kareemi M, Lawrance IC et al (2007) Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 357:239–250

    Article  CAS  PubMed  Google Scholar 

  • Schreiber S, Lawrance IC, Thomsen O et al (2011) Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 33:185–193

    Article  CAS  PubMed  Google Scholar 

  • Shah SC, Colombel JF, Sands BE, Narula N (2016) Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol pii: S1542-3565(16)00107-5 [Epub ahead of print]. doi: 10.1016/j.cgh.2016.01.015

  • Shea B, Swinden MV, Ghogomu ET et al (2014) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol 41:1049–1060

    Article  CAS  PubMed  Google Scholar 

  • Shen B, Fazio VW, Remzi FH, Bennett AE, Lopez R, Brzezinski A, Oikonomou I, Sherman KK, Lashner BA (2007) Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 50(4):498

    Article  PubMed  Google Scholar 

  • Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA (1979) National cooperative Crohn’s disease study: adverse reactions to study drugs. Gastroenterology 77:870–882

    CAS  PubMed  Google Scholar 

  • Sipponen T, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M (2008a) Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther 28:1221–1229

    Article  CAS  PubMed  Google Scholar 

  • Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M (2008b) Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 14:40–46

    Article  PubMed  Google Scholar 

  • Soler D, Chapman T, Yang LL et al (2009) The binding specificity and selective antagonism of Vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330(3):864–875

    Article  CAS  PubMed  Google Scholar 

  • Subramaniam K, D’Rozario J, Pavli P (2013) Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol 28:24–30

    Article  CAS  PubMed  Google Scholar 

  • Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW (1979) National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology 77(4 Pt 2):847–869

    CAS  PubMed  Google Scholar 

  • Targan SR, Karp LC (2005) Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 206:296–305

    Article  CAS  PubMed  Google Scholar 

  • Targan SR, Feagan BG, Fedorak RN, Lashner BA et al (2007) Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology 132(5):1672–1683

    Article  CAS  PubMed  Google Scholar 

  • Travis SP, Danese S, Kupcinskas L et al (2014) Once-daily budesonide MMX inactive, mild-to-moderate ulcerative colitis: results from the randomized CORE II study. Gut 63:433–441

    Article  CAS  PubMed  Google Scholar 

  • Truelove SC, Witts LJ (1954) Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. BMJ 2:375–378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A et al (2014) The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 147(5):990–1007

    Article  PubMed  PubMed Central  Google Scholar 

  • van Dieren JM, Kuipers EJ, Janneke N, Samsom JN et al (2006) Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 12:311–327

    Article  PubMed  Google Scholar 

  • Vieira A, Fang CB, Rolim EG, Klug WA, Steinwurz F, Rossini LG, Candelária PA (2009) Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2:221

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang MC, Zhang LY, Han W et al (2014) PRISMA – efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine 93:e326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK (2016a) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4:CD000543. doi:10.1002/14651858.CD000543.pub4

    PubMed  Google Scholar 

  • Wang Y, Parker CE, Feagan BG, MacDonald JK (2016b) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 5:CD000544. Epub ahead of print

    Google Scholar 

  • Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427–434

    Article  CAS  PubMed  Google Scholar 

  • Yi-Zhen Z, Yong-Yu L (2014) Inflammatory bowel disease: pathogenesis. World J Gastroenterol 20(1):91–99

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Houston Methodist Hospital/Weill Cornell Medical College, Houston, TX, USA

    Bincy P. Abraham

  2. UT Southwestern Medical Center, Dallas, TX, USA

    Tasneem Ahmed

  3. University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

    Tauseef Ali

Authors
  1. Bincy P. Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tasneem Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tauseef Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tauseef Ali .

Editor information

Editors and Affiliations

  1. Health Sciences Center, The University of Oklahoma, Oklahoma City, Oklahoma, USA

    Beverley Greenwood-Van Meerveld

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Abraham, B.P., Ahmed, T., Ali, T. (2017). Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-Van Meerveld, B. (eds) Gastrointestinal Pharmacology . Handbook of Experimental Pharmacology, vol 239. Springer, Cham. https://doi.org/10.1007/164_2016_122

Download citation

Publish with us

Policies and ethics

Search

Navigation